OakChart

LB Pharmaceuticals Inc

LBRXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:26 AM ET

45.07+0.13 (0.29%)
2026-11-11 16:27 CET
Market cap
1,454.39 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-141.19 USD m
Free cash flow, TTM
-143.82 USD m
EPS diluted, TTM
-4.63
P/E
-
Compare

Price

LBRX against its 20, 50 and 200-day averages
2050200beatmiss
30.0040.0050.00707K1.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LBRXclose 45.0720-day 40.2450-day 40.43200-day 33.3745.07

10.1% under 50.16 on 25 Aug 2026. Last 15 sessions, 20.5% high to low

Profile

LBRX
52-week range, 86% of the way up
14.3250.16

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

IndexRUT
Employees27
IPOSep 11, 2025
Beta0.76
ATR, 14d2.53
Rel volume0.32
Short float25.83%
Insider own25.84%
Inst own84.37%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.46B
Enterprise Value1.06B
Income-141.19M
Sales0.00M
Book/sh12.94
Cash/sh12.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees27
IPOSep 11, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.48
P/C3.61
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.78
Current Ratio14.78
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.63
EPS next Y-5.74
EPS next Q-1.85
EPS this Y-94.06%
EPS next Y5.56%
EPS next 5Y-26.57%
EPS past 3/5Y-15.94% -
Sales past 3/5Y- -
EPS Y/Y TTM-483.12%
Sales Y/Y TTM-
EPS Q/Q-1169.91%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.-10.44% -

Ownership

Insider Own25.84%
Insider Trans0.00%
Inst Own84.37%
Inst Trans7.64%
ROA-36.48%
ROE-38.80%
ROIC-33.47%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2012.02%
SMA5011.48%
SMA20035.08%
Trades-

Technical

Shs Outstand32.27M
Shs Float24.00M
Short Float25.83%
Short Ratio17.22
Short Interest6.20M
52W High50.16 -10.14%
52W Low14.32 214.82%
Volatility8.60% 6.69%
ATR (14)2.53
RSI (14)64.70
Beta0.76
Rel Volume0.32
Avg Volume360.06K
Volume21,261

Performance

Perf Week10.34%
Perf Month29.55%
Perf Quarter1.81%
Perf Half Y39.50%
Perf YTD102.48%
Perf Year182.05%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.17
Target Price58.92
Prev Close44.94
Price45.07
Change %0.29%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 09, 2026InitiatedCCanaccord GenuityBuy$65+44.2%
Oct 06, 2026InitiatedGGuggenheimBuy$80+77.5%
Oct 05, 2026DowngradeRRoth CapitalBuy → Neutral$35-22.3%
Oct 02, 2026InitiatedNNeedhamBuy$68+50.9%
Jul 21, 2026InitiatedBBMO Capital MarketsOutperform$46+2.1%
Jul 07, 2026InitiatedWWolfe ResearchOutperform$45-0.2%
Apr 27, 2026InitiatedHH.C. WainwrightBuy$45-0.2%
Apr 10, 2026InitiatedCCraig HallumBuy$36-20.1%
Jan 09, 2026InitiatedRRoth CapitalBuy
Oct 06, 2025InitiatedSStifelBuy$27-40.1%

Peers

Mkt cap
TickerCompanyMkt cap
MPLTMapLight Therapeutics Inc425.36M
ANROAlto Neuroscience Inc1.17B
ACADAcadia Pharmaceuticals Inc3.18B
NMRANeumora Therapeutics Inc86.26M
AXSMAxsome Therapeutics Inc7.79B
VNDAVanda Pharmaceuticals Inc248.53M
SPTXSeaport Therapeutics Inc1.10B
HELPHelus Pharma Inc680.92M
RLMDRelmada Therapeutics Inc460.28M
MNOVMedicinova Inc68.91M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PRENSKY ZACHARYFormer OfficerJun 09 '26Proposed Sale29.4916,500486,566Jun 09 05:41 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 104
  • LB Pharmaceuticals Inc.: Q3 Earnings Snapshot (Associated Press) -6.76% +10.29%
  • LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data (Investing.com)
  • LB Pharmaceuticals to Participate in Upcoming Investor Events (GlobeNewswire) +7.91%
  • LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102's Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress (GlobeNewswire)
  • Loading…
  • LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.54%
  • LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB-102 with a Focus on Schizophrenia Treatment (GlobeNewswire)
  • LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer (GlobeNewswire)
  • IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target? (Investor's Business Daily)
  • LB Pharmaceuticals to Participate in Upcoming September Investor Events (GlobeNewswire)
  • LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer (GlobeNewswire)
  • LB Pharmaceuticals Inc.: Q2 Earnings Snapshot (Associated Press)
  • LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.790-1.621-1.7900.000.0012
2026Q22026-08-11-1.710-0.804-1.7120.000.009
2026Q12026-05-12-0.670-0.745-0.6750.000.006
2025Q42026-03-26-0.450-0.448-0.4530.000.004
2025Q32025-11-06-0.610-0.570-0.1410.000.003
2025Q22025-09-03-1.440--0.2170.00--
2026Q4---1.855--0.0012
2027Q1---1.813--0.007
2027Q2---1.633--0.007
2027Q3---1.530--0.007
2027Q4---1.476--0.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-3.130-4.028-2.5500.000.00
2026FY--6.074--0.00
2027FY--5.737--0.00
2028FY--6.347--4.90
2029FY--6.075--70.57
2030FY--3.928--220.35

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-068000.000.000.00
2026Q4S2026-10-148000.000.000.00
2026Q4S2026-10-099000.000.000.00
2026Q4S2026-10-088000.000.000.00
2026Q4S2026-10-027000.000.000.00
2026Q4S2026-09-306000.000.000.00
2026Q4S2026-08-235000.000.000.00
2026Q4S2026-08-116000.000.000.00
2026Q4S2026-07-066000.000.000.00
2026Q4S2026-05-135000.000.000.00
2026Q4S2026-04-245000.000.000.00
2026Q4S2026-04-094000.000.000.00
2026Q4S2026-03-273000.000.000.00
2026Q4S2026-01-082000.000.000.00

Estimate history

EPS, annual-0.639-0.28-2.812-0.996-4.6259
Period2022202320242025TTM
EPS, quarterly-0.632-0.226-0.21-0.217-0.141-0.453-0.675-1.712-1.786
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual22.44322.44322.44325.29932.27
Period2022202320242025MRQ
Shares, quarterly22.44322.44325.29922.44325.29925.29928.67528.68132.27
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.390.320.090.000.00
Gross Profit-0.39-0.32-0.09-0.00-0.00
Selling, General and Administrative Excl. Other152.0030.0864.7411.372.81
Research and Development118.7916.7451.177.841.35
Other Operating Expense0.000.000.000.000.00
Operating Income-152.39-30.40-64.83-11.38-2.81
Interest Expense0.000.000.004.832.15
Unusual Expense1.21-1.160.95-8.829.46
Net Income Before Taxes-141.19-25.20-63.10-6.27-14.35
Income Taxes0.000.000.000.000.00
Consolidated Net Income-141.19-25.20-63.10-6.28-14.35
Net Income From Continuing Operations-141.19-25.20-63.10-6.28-14.35
Net Income-141.19-25.20-63.10-6.28-14.35
EPS (Recurring)-4.24-1.03-2.78-0.55-0.34
EPS (Basic, Before Extraordinaries)-4.63-1.00-2.81-0.28-0.64
EPS (Diluted)-4.63-1.00-2.81-0.28-0.64
EBITDA-152.00-30.08-64.74-11.37-2.81
Non-Operating Income (Expense)12.404.042.681.100.07
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense12.953.312.440.230.00
Shares Outstanding32.2725.3022.4422.4422.44
Market Capitalization1,454.391,454.39543.93--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.100.080.090.080.080.080.08
Gross Profit-0.12-0.10-0.08-0.09-0.08-0.08-0.08-0.08
Selling, General and Administrative Excl. Other62.3753.8222.0213.795.174.786.355.46
Research and Development51.5244.1514.648.482.422.423.420.38
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-62.50-53.91-22.10-13.87-5.25-4.86-6.43-5.54
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.340.66-0.200.40-0.980.19-0.770.19
Net Income Before Taxes-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Net Income From Continuing Operations-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
Net Income-59.07-51.60-19.05-11.47-3.56-4.87-5.31-5.07
EPS (Recurring)-1.78-1.70-0.68-0.44-0.17-0.21-0.23-0.22
EPS (Basic, Before Extraordinaries)-1.79-1.71-0.67-0.45-0.14-0.22-0.21-0.23
EPS (Diluted)-1.79-1.71-0.67-0.45-0.14-0.22-0.21-0.23
EBITDA-62.37-53.82-22.02-13.79-5.17-4.78-6.35-5.46
Non-Operating Income (Expense)3.772.972.852.800.710.180.350.66
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.634.902.571.850.880.330.641.63
Shares Outstanding32.2728.6828.6725.3025.3022.4425.3022.44
Market Capitalization1,454.39930.70707.12563.16354.38342.03--

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments295.2128.0043.2921.40
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets13.220.882.340.09
Total Current Assets308.4328.8845.6321.49
Net Property, Plant & Equipment3.734.160.020.00
Total Investments and Advances0.770.500.000.00
Long-Term Note Receivable--0.00-
Intangible Assets0.000.000.000.00
Other Assets0.000.000.010.00
Total Assets312.9333.5345.6621.49
Short Term Debt Incl. Current Port. of LT Debt0.730.490.000.00
Accounts Payable2.132.321.390.16
Other Current Liabilities4.585.301.220.31
Total Current Liabilities7.448.112.610.47
Long Term Debt2.843.220.0024.15
Provision for Risks Charges0.000.000.000.00
Other Liabilities1.342.501.5618.49
Total Liabilities11.6213.834.1643.11
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00114.2675.977.19
Common Equity301.31-94.55-34.47-28.81
Total Shareholders Equity301.3119.7041.49-21.62
Accumulated Minority Interest0.000.000.000.00
Total Equity301.3119.7041.49-21.62
Total Liabilities & Stockholders Equity312.9333.5345.6621.49
Book Value Per Share11.91-4.21-1.54-1.28
Tangible Book Value Per Share11.91-4.21-1.54-1.28
Full-Time Employees2716--
Price to Book Ratio3.471.75--
Return on Assets-14.55-159.37-18.69-
Return on Equity-15.70-206.22-63.14-
Return on Invested Capital-8.29-275.30-15.12-567.11
Quick Ratio41.443.5617.5145.82
Current Ratio41.443.5617.5145.82

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-141.19-25.20-63.10-6.28-14.35
Depreciation0.390.320.090.000.00
Other Funds (Non Cash)14.553.336.65-4.5111.53
Funds from Operations-126.26-21.56-56.37-10.78-2.81
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-17.06-13.653.31-1.310.09
Cash from Operating Activities-143.31-35.21-53.05-12.09-2.73
Capital Expenditures-0.51-0.05-0.77-0.030.00
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-144.13-39.8424.00-27.980.12
Purchase of Investments-166.14-44.84-29.75-33.980.00
Sale Or Maturity of Investments22.015.0053.756.000.12
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-144.64-39.8923.23-28.010.12
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock233.56302.5638.3133.040.62
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock233.56302.5638.3133.040.62
Proceedsfrom Stock Options233.44302.3138.2933.040.62
Issuance or Reduction of Debt, Net0.000.000.000.6422.34
Change in Long Term Debt0.000.000.000.6422.34
Issuance of Long Term Debt0.000.000.000.6422.34
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities233.56302.5638.3133.6822.96
Net Change in Cash-54.39227.478.50-6.4220.36
Free Cash Flow-143.82-35.26-53.82-12.12-2.73
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments403.76327.79365.64295.21314.48-
Short Term Receivables0.000.000.000.000.00-
Inventories0.000.000.000.000.00-
Other Current Assets43.3627.5123.4413.221.92-
Total Current Assets447.12355.30389.07308.43316.40-
Net Property, Plant & Equipment5.465.613.633.733.83-
Total Investments and Advances0.790.780.780.770.51-
Intangible Assets0.000.000.000.000.00-
Other Assets0.000.000.000.000.00-
Total Assets453.37361.69393.48312.93320.75-
Short Term Debt Incl. Current Port. of LT Debt0.960.840.730.730.73-
Accounts Payable6.883.497.122.132.59-
Other Current Liabilities22.4119.233.064.583.33-
Total Current Liabilities30.2523.5610.917.446.65-
Long Term Debt4.204.372.742.842.94-
Provision for Risks Charges0.000.000.000.000.00-
Other Liabilities1.281.411.141.340.94-
Total Liabilities35.7329.3414.7911.6210.53-
Non-Equity Reserves0.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.000.00-
Common Equity417.64332.35378.69301.31310.22-
Total Shareholders Equity417.64332.35378.69301.31310.22-
Accumulated Minority Interest0.000.000.000.000.00-
Total Equity417.64332.35378.69301.31310.22-
Total Liabilities & Stockholders Equity453.37361.69393.48312.93320.75-
Book Value Per Share12.9411.5913.2111.9112.26-
Tangible Book Value Per Share12.9411.5913.2111.9112.26-
Full-Time Employees---27--
Price to Book Ratio3.472.462.071.82--
Return on Assets-36.48---14.55--
Return on Equity-38.80---15.70--
Return on Invested Capital-14.00-15.33-5.00-3.77-1.14-
Quick Ratio14.7815.0835.6841.4447.60-
Current Ratio14.7815.0835.6841.4447.60-

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-59.07-51.60-19.05-11.47-3.56-4.87
Depreciation0.120.100.080.090.080.08
Other Funds (Non Cash)3.725.592.432.810.200.45
Funds from Operations-55.23-45.92-16.54-8.57-3.28-4.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-9.078.29-6.75-9.53-0.10-1.25
Cash from Operating Activities-64.29-37.63-23.29-18.10-3.37-5.60
Capital Expenditures-0.07-0.36-0.03-0.040.000.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-144.580.450.000.00-44.840.00
Purchase of Investments-156.40-9.750.000.00-44.840.00
Sale Or Maturity of Investments11.8110.200.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-144.650.09-0.03-0.04-44.840.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock140.92-0.0293.83-1.17303.730.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock140.92-0.0293.83-1.17303.730.00
Proceedsfrom Stock Options140.87-0.0793.80-1.17303.490.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities140.92-0.0293.83-1.17303.730.00
Net Change in Cash-68.03-37.5670.51-19.31255.52-5.59
Free Cash Flow-64.36-37.99-23.32-18.14-3.37-5.59

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.83%6.2M24.0M367.61K
2026-10-1523.26%5.6M23.9M371.55K
2026-09-3025.13%6.0M23.9M334.72K
2026-09-1523.48%5.6M23.9M343.04K
2026-08-3122.07%5.3M23.9M326.59K
2026-08-1421.56%5.2M23.9M315.33K
2026-07-3122.87%4.7M20.8M266.85K
2026-07-1520.52%4.3M20.8M244.82K
2026-06-3021.92%4.6M20.8M263.70K
2026-06-1520.73%4.3M20.8M231.96K
2026-05-2919.34%4.0M20.8M239.97K
2026-05-1519.36%4.0M20.8M248.35K
2026-04-3017.83%3.8M21.3M258.42K
2026-04-1514.60%3.1M21.3M245.29K
2026-03-3112.30%2.6M21.3M229.51K
2026-03-1314.43%2.7M18.8M307.24K
2026-02-2713.91%2.6M18.8M309.39K
2026-02-1311.70%2.2M18.8M295.74K
2026-01-309.60%1.8M18.8M281.58K
2026-01-159.53%1.8M18.8M262.56K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call22.5020.3025.000.005.1970.000.000.882-0.5330.014
call25.0017.8022.500.004.5890.000.000.863-0.5240.016
call30.0012.8017.500.003.4240.000.000.820-0.4940.019
call35.008.0012.500.002.7490.000.000.766-0.4480.022
call40.003.308.001.751.9072270.000.689-0.3810.025
call45.000.105.002.001.7614.001.000.558-0.2760.028
call50.000.005.000.002.3800.000.000.471-0.3740.028
call55.000.005.000.002.9340.000.000.421-0.4490.028
call60.000.005.000.003.3190.000.000.392-0.5020.027
call65.000.005.000.003.6930.000.000.370-0.5480.027
put22.500.005.000.006.8670.000.00-0.118-0.5310.014
put25.000.005.000.606.1041.000.00-0.136-0.5220.016
put30.000.005.000.004.8170.000.00-0.178-0.4920.019
put35.000.005.002.073.7132.000.00-0.234-0.4440.022
put40.000.005.003.002.73552.000.00-0.312-0.3760.025
put45.000.305.000.001.7840.000.00-0.442-0.2710.028
put50.003.607.500.001.5530.000.00-0.532-0.3730.028
put55.007.5012.500.002.0600.000.00-0.578-0.4430.028
put60.0012.8017.200.002.2460.000.00-0.609-0.4970.027
put65.0017.6022.200.002.6330.000.00-0.630-0.5420.027

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-09SEC
2026-10-13SCHEDULE 13G/ASEC
2026-10-05EFFECTEffectiveness filing by commission orderSEC
2026-10-01POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-10-01S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-09-243Initial statement of beneficial ownership of securities2026-09-14SEC
2026-09-15424B3SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-143Initial statement of beneficial ownership of securities2026-09-02SEC
2026-09-03424B3SEC
2026-09-038-KCurrent report2026-09-03SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-11424B3SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-29424B3SEC
2026-07-298-KCurrent report2026-07-28SEC
2026-07-22424B3SEC
2026-07-228-KCurrent report2026-07-22SEC
2026-07-16SCHEDULE 13GSEC
2026-06-10424B3SEC
2026-06-108-KCurrent report2026-06-08SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-09424B3SEC
2026-06-098-KCurrent report2026-06-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Deep Track Capital, LP11.69%
BlackRock, Inc.9.53%
RA CAPITAL MANAGEMENT, L.P.7.70%
Nantahala Capital Management, LLC7.34%
Trails Edge Capital Partners, LP5.31%
Commodore Capital LP5.23%
JPMORGAN CHASE & CO5.22%
TCG Crossover Management, LLC5.05%
Caligan Partners LP5.01%
Spruce Street Capital LP4.80%

Funds

Fund% owned
JPMorgan Small Cap Growth Fund2.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.34%
iShares Russell 2000 ETF2.03%
BlackRock Health Sciences Opportunities Portfolio1.76%
VANGUARD EXTENDED MARKET INDEX FUND0.97%
Fidelity Small Cap Index Fund0.85%
JPMorgan Small Cap Blend Fund0.77%
BlackRock Health Sciences Term Trust0.73%
PGIM Jennison Health Sciences Fund0.72%
Fidelity Growth Company Fund0.62%

OakChart. LBRX. Cached 15 minutes.